Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

References for PMC Articles for PubMed (Select 21258105)

1.

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L.

JAMA. 2010 Sep 8;304(10):1082-90. doi: 10.1001/jama.2010.1278.

2.

Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.

MacLeod IJ, Rowley CF, Thior I, Wester C, Makhema J, Essex M, Lockman S.

J Clin Virol. 2010 Jul;48(3):162-7. doi: 10.1016/j.jcv.2010.03.017. Epub 2010 Apr 27.

3.

Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.

Jourdain G, Wagner TA, Ngo-Giang-Huong N, Sirirungsi W, Klinbuayaem V, Fregonese F, Nantasen I, Techapornroong M, Halue G, Nilmanat A, Wittayapraparat P, Chalermpolprapa V, Pathipvanich P, Yuthavisuthi P, Frenkel LM, Lallemant M; Program for HIV Prevention and Treatment (PHPT) Study Group.

Clin Infect Dis. 2010 May 15;50(10):1397-404. doi: 10.1086/652148.

4.

Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.

Rowley CF, Boutwell CL, Lee EJ, MacLeod IJ, Ribaudo HJ, Essex M, Lockman S.

AIDS Res Hum Retroviruses. 2010 Mar;26(3):293-300. doi: 10.1089/aid.2009.0082.

5.

Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.

Kuhn L, Semrau K, Ramachandran S, Sinkala M, Scott N, Kasonde P, Mwiya M, Kankasa C, Decker D, Thea DM, Aldrovandi GM.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):132-6. doi: 10.1097/QAI.0b013e3181ab6d5e.

6.

Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1.

Wind-Rotolo M, Durand C, Cranmer L, Reid A, Martinson N, Doherty M, Jilek BL, Kagaayi J, Kizza A, Pillay V, Laeyendecker O, Reynolds SJ, Eshleman SH, Lau B, Ray SC, Siliciano JD, Quinn TC, Siliciano RF.

J Infect Dis. 2009 May 1;199(9):1301-9. doi: 10.1086/597759.

7.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS.

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

8.

Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.

Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L.

Clin Infect Dis. 2009 Feb 15;48(4):462-72. doi: 10.1086/596486.

9.

Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.

Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, Thakar M, Bharadwaj R, Kagal A, Bhore AV, Patil S, Kulkarni V, Venkataramani V, Balasubramaniam U, Suryavanshi N, Ziemniak C, Gupte N, Bollinger R, Persaud D.

PLoS One. 2009;4(1):e4096. doi: 10.1371/journal.pone.0004096. Epub 2009 Jan 1.

10.

Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.

Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV, Bhosale R, Varadhrajan V, Gupte N, Sastry J, Suryavanshi N, Tripathy S, Mmiro F, Mubiru M, Onyango C, Taylor A, Musoke P, Nakabiito C, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwerski S.

Lancet. 2008 Jul 26;372(9635):300-13. doi: 10.1016/S0140-6736(08)61114-9.

PMID:
18657709
11.

Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.

Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q, Mipando L, Nkanaunena K, Mebrahtu T, Bulterys M, Fowler MG, Taha TE.

N Engl J Med. 2008 Jul 10;359(2):119-29. doi: 10.1056/NEJMoa0801941. Epub 2008 Jun 4.

12.

Update of the drug resistance mutations in HIV-1: Spring 2008.

Johnson VA, Brun-Vezinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2008 Apr-May;16(1):62-8. No abstract available. Erratum in: Top HIV Med. 2008 Oct-Nov;16(4):121.

13.

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.

Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F; Ghent Group on HIV in Women and Children.

Int J Epidemiol. 2007 Oct;36(5):1009-21. Epub 2007 May 28. Review.

14.

Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.

Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, Bulterys M, Zulu I, Kankasa C, Wilfert C, Weidle PJ, Vermund SH, Stringer JS.

AIDS. 2007 May 11;21(8):957-64.

15.

Response to antiretroviral therapy after a single, peripartum dose of nevirapine.

Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, Essex M.

N Engl J Med. 2007 Jan 11;356(2):135-47.

16.
17.

Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.

Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, Mellors J, Morris L, Coffin J.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):7094-9. Epub 2006 Apr 25.

18.

Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.

Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L.

AIDS. 2006 Apr 24;20(7):995-1002.

19.

Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH.

J Infect Dis. 2005 Jul 1;192(1):24-9. Epub 2005 Jun 1.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk